River Global Investors LLP Lowers Stock Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

River Global Investors LLP decreased its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 34.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,948 shares of the company's stock after selling 3,686 shares during the quarter. River Global Investors LLP's holdings in GE HealthCare Technologies were worth $543,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of GEHC. Ashton Thomas Securities LLC acquired a new stake in GE HealthCare Technologies in the 3rd quarter worth about $26,000. Capital Performance Advisors LLP purchased a new position in shares of GE HealthCare Technologies in the third quarter valued at approximately $26,000. Darwin Wealth Management LLC acquired a new stake in shares of GE HealthCare Technologies in the third quarter worth approximately $31,000. Continuum Advisory LLC boosted its stake in shares of GE HealthCare Technologies by 101.8% in the third quarter. Continuum Advisory LLC now owns 333 shares of the company's stock worth $31,000 after acquiring an additional 168 shares during the last quarter. Finally, Bank of Jackson Hole Trust purchased a new stake in shares of GE HealthCare Technologies during the fourth quarter worth approximately $32,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on GEHC shares. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a "hold" rating to a "buy" rating and increased their target price for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. Wells Fargo & Company increased their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Finally, Citigroup boosted their target price on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, GE HealthCare Technologies currently has an average rating of "Moderate Buy" and a consensus target price of $97.67.

Remove Ads

GE HealthCare Technologies Trading Down 1.4 %

GE HealthCare Technologies stock traded down $1.25 during mid-day trading on Monday, hitting $85.33. The company's stock had a trading volume of 2,621,660 shares, compared to its average volume of 2,965,977. The stock's fifty day moving average is $86.77 and its two-hundred day moving average is $86.16. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $39.02 billion, a PE ratio of 19.71, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13. GE HealthCare Technologies Inc. has a 1 year low of $74.51 and a 1 year high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.19. The firm had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. On average, analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.